Lifecare ASA

LIFE Successful in-vitro quality testing of sensor

Bergen, Norway, June 13th, 2024: Today, Lifecare ASA (LIFE), a clinical stage

medical sensor company developing the next generation Continuous Glucose

Monitor (CGM), announces that the company has concluded a successful in-vitro

quality test of sensor for use in longevity study.

Reference is made to stock exchange notification June 10th, 2024. The internal

in-vitro quality test has been successfully conducted.

About us

Lifecare ASA is a clinical stage medical sensor company developing technology

for sensing and monitoring of various body analytes. Lifecare's main focus is

to bring the next generation of Continuous Glucose Monitoring ("CGM") systems

to market. Lifecare enables osmotic pressure as sensing principle, combined

with the ability to manipulate Nano-granular Tunnelling Resistive sensors

("NTR") on the sensor body for read-out of pressure variations. Lifecare's

sensor technology is referred to as "Sencell" and is suitable for identifying

and monitoring the occurrence of a wide range of analytes and molecules in the

human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, [email protected], +47 40 05 90 40

Renete Kaarvik, CFO, [email protected], +47 94 83 82 42

This information has been submitted pursuant to the Securities Trading Act §

5-12 and MAR Article 19 no. 3. The information was submitted for publication

at 2024-06-13 14:33 CEST.

AI Terminal